New drug KAI-1678 tested for spinal cord injury pain
NCT ID NCT01135108
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 2 trial tested whether KAI-1678, given as a single injection under the skin, can reduce pain in people with spinal cord injury. Only 5 adults with long-term spinal cord injury and chronic pain took part. The study compared KAI-1678 to a placebo to see if it improved pain scores.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KAI-1678
- What this could lead to
- If it works, this could point toward a new pain treatment for people with spinal cord injury.
- What could go wrong
- This is a very small, early Phase 2 trial with only 5 participants, so results may not apply broadly. The drug may not reduce pain better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Sydney, New South Wales, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'Smart Bridge' in the spine help paralyzed patients walk again?
- Spinal zaps may steady blood pressure in spinal cord injury
- Can a simple pill stabilize blood pressure after spinal cord injury?
- Can breathing power boost balance and Well-Being in paralympic athletes?
- Spinal implant + robot rehab: a new hope for walking after injury?
- Can a robotic suit plus spinal stimulation help paralyzed individuals walk again?